Alzheimers disease
Conditions
Interventions
Take Rifampicin 150mg capsule or Placebo capsule once daily 2 capsules for 12 weeks
Riboflavin butyrate tablet 20 mg once daily 1 tablet for 12 weeks
Sponsors
Iwata Atsushi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Written informed consent to the participation in this research has been provided 2) Men and women aged 65 or over at the time of obtaining informed consent 3) Person who has been determined to have the pathology of Alzheimer's disease based on amyloid Beta 42/40 and the concentration of p-tau181 in the cerebrospinal fluid
Exclusion criteria
Exclusion criteria: 1) Person who has been judged to have dementia by CogState 2) Person who has been diagnosed with dementia in the last 5 years 3) Person with liver dysfunction with more than 3 times the upper limit of the normal range of ALT or AST 4) Person with renal dysfunction with less than 50 ml / min of eGFR 5) Person with a history of hypersensitivity to Rifampicin 6) Person who has taken Rifampicin within the last 4 weeks 7) Person whose inclusion in the research is deemed inappropriate by the principal investigator or sub-investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in cerebrospinal fluid neurofilament light from before and 12 weeks after the start of study drug administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the following biomarkers from before and 12 weeks after the start of study drug administration cerebrospinal fluid: amyloid Beta oligomer, tau oligomer, amyloid Beta42, amyloid Beta40, p-tau 181, YKL-40, IL-6 blood: p-tau 181, neurofilament light Incidence of adverse events Changes in cognitive function from before and 12 weeks after study drug administration | — |
Contacts
Public ContactAtsushi Iwata
Medical Co. LTA Sumida Hospital
Outcome results
None listed